What are your top takeaways from ISTH 2025?
2 Answers
Mednet MemberInvited Expert
Hematology · University of Rochester School of Medicine and Dentistry
Answered on
- MAYARI trial - this trial was a single-arm trial for "non-severe" iTTP (excluding patients with significant cardiac or neurologic involvement) where PLEX was only used as a rescue therapy. Patients were started on caplacizumab and immunosuppression with steroids and rituximab. A large number of patients were able to avoid PLEX entirely. My main concern with caplacizumab is safety (causes an acquired type 2M von Willebrand). The safety profile was quite good (32% with bleeds; but no ICH in pati...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Hematology · Albert Einstein College of Medicine
Answered on
- Session code 13394 - Extended Reduced vs Full Dose oral anticoagulant after VTE in obese patients (RENOVE trial)
- Session code 12636 - Bleeding risk on rivaroxaban and apixaban in older patients with VTE (Roupe et al.)
- Session Code 14299 - Major surgical outcomes with efanesoctocog alfa (Klamroth et al.)
Join for free or sign in to see the full answer